- Tel: 858.663.9055
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
A2M Antibody reagents target alpha-2-macroglobulin (A2M), a large plasma glycoprotein and broad-spectrum protease inhibitor. A2M belongs to the macroglobulin superfamily and is abundant in blood, cerebrospinal fluid, and other body fluids. Its primary function is to trap and inactivate proteases through a unique “bait and trap” mechanism, forming stable complexes that are then cleared via receptor-mediated endocytosis.
Beyond protease inhibition, A2M plays roles in modulating immune responses, binding growth factors, and regulating inflammation. Its interactions extend to cytokines, hormones, and amyloid proteins, positioning it as a multifunctional regulator at the interface of immunity and proteostasis.
Because of these broad roles, the A2M Antibody is a crucial tool for studies in hematology, inflammation, neurodegeneration, cancer, and biomarker research. The Alpha-2-Macroglobulin Antibody provides complementary detection across diverse assay platforms.
NSJ Bioreagents provides A2M Antibodies validated for immunohistochemistry (IHC), western blotting (WB), immunofluorescence (IF), flow cytometry (FACS), and ELISA. Each antibody is rigorously tested for specificity, reproducibility, and cross-platform consistency.
Key benefits include:
Biomarker Utility: Detects a clinically relevant plasma protein.
Assay Versatility: Works across tissue sections, blood samples, and cell models.
Reproducibility: Batch-to-batch consistency for reliable research outcomes.
Comprehensive Documentation: Protocols, recommended controls, and validation data.
Clinical Relevance: Supports biomarker discovery and translational research.
With NSJ Bioreagents, scientists can trust the A2M Antibody for dependable performance in both basic and applied studies.
The A2M Antibody supports diverse applications spanning protease biology, clinical diagnostics, and translational pipelines.
Detect A2M’s role in binding serine, cysteine, and metalloproteases.
Support studies of protease regulation in coagulation and fibrinolysis.
Provide biomarkers for systemic protease activity.
Extend into translational protease research.
A2M Antibody detects expression changes during acute-phase responses.
Supports studies of cytokine modulation and inflammatory cascades.
Provides biomarkers for chronic inflammatory disease.
Extends into translational immunology pipelines.
Detect A2M in cerebrospinal fluid as a biomarker for Alzheimer’s and Parkinson’s disease.
Support studies of amyloid binding and clearance.
Provide biomarkers for neurodegenerative disease progression.
Extend into translational neuroscience pipelines.
A2M Antibody detects roles in coagulation and vascular remodeling.
Supports studies of thrombosis and atherosclerosis.
Provides biomarkers for cardiovascular disease risk.
Extends into translational cardiology pipelines.
Detect altered A2M expression in cancer tissues and plasma.
Support studies of tumor-associated protease regulation.
Provide biomarkers for cancer progression and metastasis.
Extend into translational oncology pipelines.
A2M Antibody supports plasma assays for biomarker discovery.
Provides reproducibility in translational and diagnostic pipelines.
Ensures reliability in studies linking A2M to clinical outcomes.
Bridges laboratory research with clinical diagnostics.
Detect A2M modulation during viral and bacterial infections.
Support studies linking protease regulation to pathogen control.
Provide biomarkers for infection-driven inflammation.
Extend into translational infectious disease pipelines.
A2M acts as a systemic regulator of protease and cytokine activity.
Antibodies validate therapeutic targeting of protease–A2M interactions.
Provide biomarkers for therapeutic monitoring.
Extend into pharmaceutical pipelines.
A2M is a multifunctional plasma protein at the crossroads of protease inhibition, inflammation, and biomarker biology. The A2M Antibody provides validated tools to explore these roles across multiple systems.
In immunology, it clarifies how A2M modulates cytokine and protease cascades. In neuroscience, it highlights its role in amyloid clearance and neurodegeneration. In oncology, it underscores how tumors exploit protease balance for invasion. In cardiology, it links A2M expression to thrombosis and vascular pathology.
Clinically, A2M is emerging as a biomarker for neurodegeneration, inflammation, and systemic disease. Reliable Alpha-2-Macroglobulin Antibody reagents ensure reproducibility across research, translational, and diagnostic pipelines.
A2M is a broad-spectrum protease inhibitor and multifunctional plasma protein linked to immunity, neurodegeneration, and cancer. The A2M Antibody provides validated reagents for inflammation, biomarker, and translational research, while the Alpha-2-Macroglobulin Antibody complements these applications across multiple platforms. By ensuring specificity, reproducibility, and versatility, these antibodies remain indispensable for advancing clinical and translational science.
Analysis of a HuProt(TM) microarray containing more than 19,000 full-length human proteins using A2M antibody (Cat # V4242, clone A2M/4847).
| ||
![]() |
| ||
![]() |